Characterization of Metabolic Differences between Benign and Malignant Tumors: High-Spectral-Resolution Diffuse Optical Spectroscopy

• Published in: Radiology Vol. 254; no. 1; pp. 277 - 284
• Main Authors: Kukreti, Shwayta, Cerussi, Albert E., Tanamai, Wendy, Hsiang, David, Tromberg, Bruce J., Gratton, Enrico
• Format: Journal Article
• Language: English
• Published: Oak Brook, IL Radiological Society of North America 01.01.2010; Radiological Society of North America, Inc
• Subjects: Adult; Aged; Algorithms; Biological and medical sciences; Biomarkers, Tumor - metabolism; Breast Neoplasms - metabolism; Breast Neoplasms - pathology; Case-Control Studies; Discriminant Analysis; False Positive Reactions; Female; Genital system. Mammary gland; Gynecology. Andrology. Obstetrics; Humans; Investigative techniques, diagnostic techniques (general aspects); Mammary gland diseases; Medical sciences; Middle Aged; Original Research; Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques; Predictive Value of Tests; Sensitivity and Specificity; Spectroscopy, Near-Infrared - instrumentation; Statistics, Nonparametric; Tumors; Human; Optical spectrometry; High resolution; Breast disease; Breast tumor; Exploration; Malignant tumor; Metabolism; Differential diagnostic; Mammary gland diseases; Near infrared spectrometry; Sensitivity; Specificity; Breast; Mammary gland; Benign neoplasm; Predictive factor; Cancer
• ISSN: 0033-8419; 1527-1315; 1527-1315
• DOI: 10.1148/radiol.09082134

To develop a near-infrared spectroscopic method to identify breast cancer biomarkers and to retrospectively determine if benign and malignant breast lesions could be distinguished by using this method. The study was HIPAA compliant and was approved by the university institutional review board. Written informed consent was obtained. By using self-referencing differential spectroscopy (SRDS) analysis, the existence of specific spectroscopic signatures of breast lesions on images acquired by using diffuse optical spectroscopy imaging in the wavelength range (650-1000 nm) was established. The SRDS method was tested in 60 subjects (mean age, 38 years; age range, 22-74 years). There were 17 patients with benign breast tumors and 22 patients with malignant breast tumors. There were 21 control subjects. Discrimination analysis helped separate malignant from benign tumors. A total of 40 lesions (22 malignant and 18 benign) were analyzed. Twenty were true-positive lesions, 17 were true-negative lesions, one was a false-positive lesion, and two were false-negative lesions (sensitivity, 91% [20 of 22]; specificity, 94% [17 of 18]; positive predictive value, 95% [20 of 21]; and negative predictive value, 89% [17 of 19]). The SRDS method revealed localized tumor biomarkers specific to pathologic state.